Natera's Signatera Identifies Breast Cancer Patients Eligible for Non-Surgical Treatment — Natera, Inc.

Event summary

Natera's Signatera test identified 68% of early-stage ER+/HER2- breast cancer patients as MRD-negative, allowing them to forgo surgery.
Among baseline MRD-positive patients, 64% cleared circulating-tumor DNA after 6 months of primary endocrine therapy (pET).
Signatera detected all tumor progressions before imaging in a prospective study of 43 women aged 70+ with stage 1-3 breast cancer.
Over 80% of patients reported that Signatera helped inform treatment decisions without increased anxiety.

The big picture

Natera's study validates Signatera as a critical tool for risk stratification and monitoring in early-stage breast cancer, potentially reducing the need for surgery in select patients. This aligns with broader trends toward personalized medicine and non-invasive diagnostic approaches in oncology. The findings could expand Natera's market opportunities in precision oncology, particularly among older patients prioritizing quality of life.

What we're watching

Clinical Adoption: How quickly Signatera will be integrated into standard care protocols for breast cancer management.
Reimbursement Dynamics: Whether payers will cover Signatera testing as a routine monitoring tool for non-surgical patients.
Competitive Positioning: The pace at which Natera can expand Signatera's use cases beyond breast cancer into other oncology indications.